Clinical trials of bococizumab

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods	
bococizumab vs placebo				
SPIRE-1 ongoing [NCT01975376] n=NA follow-up:	Bococizumab versus placebo	high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C >/= 70 mg/dL (1.8 mmol/L) and <100 mg/dL (2.6 mmol/L) or non-HDL-C >/= 100 mg/dl (2.6 mmol/L) and <130 mg/dL (3.4 mmol/L).	double-blind	
SPIRE-2 ongoing [NCT01975389] n=NA follow-up:	bococizumab versus Placebo	high risk subjects who are receiving background lipid lowering therapy and have cholesterol laboratory values of LDL-C >/= 100 mg/dL (2.6 mmol/L) or non-HDL-C >/=130 mg/dL (3.4 mmol/L).	double-blind	
SPIRE-FH ongoing [NCT01968980] n=NA follow-up:	-	subjects with heterozygous familial hypercholesterolemia receiving highly effective statins	double-blind US	
SPIRE-HR ongoing [NCT01968954] n=NA follow-up:	Bococizumab versus Placebo	subjects with high cholesterol receiving highly effective statins	double-blind US	
SPIRE-LDL ongoing [NCT01968967] n=NA follow-up:	-	subjects with high cholesterol receiving highly effective statins	double-blind US	
SPIRE-LL ongoing [NCT02100514] n=NA follow-up:	-	subjects with hyperlipidemia receiving background statin therapy	double-blind US	

continued...

n=NA
follow-up:

Trial

Treatments Bococizumab

Patients

Trials design and methods

double-blind

SPIRE-SI ongoing [NCT02135029] n=NA

versus Placebo

More details and results:

• PCSK9 Inhibitors for cardiovascular prevention in all type of patients at http://www.trialresultscenter.org/go-Q599

References

SPIRE-1, 0:

ongoing trial NCT01975376

SPIRE-2, 0:

ongoing trial NCT01975389

SPIRE-FH, 0:

ongoing trial NCT01968980

SPIRE-HR, 0:

ongoing trial NCT01968954

SPIRE-LDL, 0:

ongoing trial NCT01968967

SPIRE-LL, 0:

ongoing trial NCT02100514

SPIRE-SI, 0:

ongoing trial NCT02135029

Entry terms: bococizumab,

 \sim